Camurus announces positive results from POSITANO phase 2b study of octreotide SC depot in patients with symptomatic polycystic liver disease: Lund, Sweden Thursday, June 19, 2025, ...

UK study suggests that patients with prolactinoma treated with dopamine agonists are more likely to develop impulse control disorders ...

CAM2029 reduces liver and cyst volume growth compared to placebo Well tolerated with no new or unexpected safety findingsA follow-up Phase 3 study will be discussed with regulatory authoritiesLUND ...

Camurus (NASDAQ STO: CAMX) today announced topline results from the 12-month, randomized, double-blind, placebo-controlled POSITANO Phase ...

Crinetics Pharmaceuticals trades at a steep discount while maintaining strong analyst support and a ~$3B valuation. Learn why ...

Cumulative exposure to IGF-1 excess was associated with a higher cancer risk among patients with acromegaly. Patients with acromegaly have a much higher cancer prevalence than those with ...

The study included a total of 135 patients with acromegaly who were biochemically controlled (IGF-1≤1xULN) or uncontrolled on stable doses of standard-of-care (SoC) with first generation ...

Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients ...

Incidence of benign tumors in acromegaly is increased more than two fold. In patients with acromegaly, some studies have also shown an increased cancer prevalence (4.8% to 21%) and a link between ...